Skip to main content

RED TEMATICA DE ANTIVIRALES FRENTE A ENFERMEDADES ARBOVIRALES

SAF2016-81856-REDT

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Redes Investigación /Redes Excelencia
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Development of antivirals: medicinal chemistry at the beginning of the process¿and beyond

  • Peréz-Pérez, María-Jesús
The role of medicinal chemistry in drug discovery is crucial but there is significant discussion these days about how far medicinal chemists should be involved in the development process.1 The advances of the different disciplines accompanying drug discovery besides medicinal chemistry itself such as molecular biology, computational chemistry, pharmacokinetics and metabolism studies among others, have increased the challenges to be faced by medicinal chemists. Antiviral drug development has special characteristics when compared to other therapeutic fields in drug discovery. As an example, in a recent review article asking where do recent small molecule clinical development candidates come from,2 it is indicated that phenotypic screening is still one of the main source of antivirals while for other therapeutic areas target-based or fragment-based screening are becoming more relevant. Once a hit with antiviral properties has been identified, its optimization to become a lead is a multiparameter process, that can also be determined by the mechanism of action of the compound. Recent selected examples of the development of antivirals from the literature will be used to highlight this process. In addition, our own experience in triazolopyrimidines as inhibitors of CHIKV replication will be presented to illustrate how proactive and collaborative efforts among academic groups can lead to the identification and optimization of antivirals exploring a new mechanism of action.3-6, Our project in CHIKV inhibitors is financed by a grant from MINECO/FEDER SAF2015-64629-C2-1-R. We also acknowledge the support to REARBOVIR (SAF2016-81856-REDT), a network for antivirals against arboviral diseases
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Nanomaterials for biomedical applications

  • Fuente, Jesús M. de la
Trabajo presentado al 2nd REARBOVIR Workshop, celebrado del 10 al 11 de marzo de 2020 en Zaragoza., Financed by Agencia Estatal de Investigación. REF: SAF2016-81856-REDT, Peer reviewed